1. Home
  2. JAGX vs RDHL Comparison

JAGX vs RDHL Comparison

Compare JAGX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.32

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$1.05

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
RDHL
Founded
2013
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.0M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
JAGX
RDHL
Price
$0.32
$1.05
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
476.7K
39.0K
Earning Date
04-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
N/A
EPS
N/A
N/A
Revenue
$11,511,000.00
N/A
Revenue This Year
$61.58
$381.91
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.71
52 Week High
$13.25
$3.31

Technical Indicators

Market Signals
Indicator
JAGX
RDHL
Relative Strength Index (RSI) 31.21 70.57
Support Level N/A $0.79
Resistance Level $0.46 $1.07
Average True Range (ATR) 0.04 0.06
MACD 0.00 0.03
Stochastic Oscillator 0.58 86.20

Price Performance

Historical Comparison
JAGX
RDHL

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: